Item 1.01 | Entry Into a Material Definitive Agreement |
On April 6, 2023, Bed Bath & Beyond Inc. (the “Company”) entered into an amendment (the “Fifth Amendment”) to that certain Amended and Restated Credit Agreement, dated as of August 9, 2021 (as amended or otherwise modified to date, the “Credit Agreement” and as further amended by the Fifth Amendment, the “Amended Credit Agreement”), with certain of the Company’s US and Canadian subsidiaries party thereto, JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”), Sixth Street Specialty Lending, Inc., as FILO agent (the “FILO Agent”), and the lenders party thereto. The Fifth Amendment permitted the entry into an amendment to the Consignment Agreement, dated as of April 4, 2023 (the “Consignment Agreement”), by and among the Company, certain of its subsidiaries and Restore Capital (BBB), LLC. The Fifth Amendment also added an Event of Default under the Amended Credit Agreement in the event that the Consignment Agreement is not extended at least fifteen days prior to the termination date therein. Additionally, from the date that the Consignment Agreement is terminated until the Company pays the Buy-Out Price (as defined in the Consignment Agreement), a reserve equal to the amount of the Buy-Out Price and any outstanding fees due and payable to the consignor under the Consignment Agreement will be implemented.
The foregoing description of the Fifth Amendment (including the Amended Credit Agreement) does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment (including the Amended Credit Agreement), a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Purchase Agreement Closing
As previously reported, on March 30, 2023, the Company entered into the Common Stock Purchase Agreement (the “Purchase Agreement”), by and between the Company and B. Riley Principal Capital II, LLC (“BRPC II”). From time to time during the term of the Purchase Agreement, the Company will have the right to sell to BRPC II, up to the lesser of (i) $1 billion of newly issued shares of common stock (the “Total Commitment”), and (ii) the Exchange Cap (as defined below) (subject to certain conditions and limitations), following the satisfaction of certain conditions set forth in the Purchase Agreement, including (i) that the registration statement on Form S-1 relating to the resale by BRPC II of shares of common stock issued to it by the Company under the Purchase Agreement is declared effective by the Securities and Exchange Commission and (ii) that the Company has issued shares of common stock to BRPC II in an amount representing 0.25% of the Total Commitment, divided by the volume weighted average price of the common stock during the five (5) consecutive trading days (y) immediately following a reverse stock split of the common stock or (z) if no such reverse stock split occurs, immediately prior to the commencement date of sales of shares pursuant to the Purchase Agreement, adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction (in each case, rounded to the nearest whole share), as consideration for BRPC II’s commitment to purchase shares of common stock at the Company’s discretion under the terms of the Purchase Agreement. Sales of common stock to BRPC II pursuant to the Purchase Agreement, and the timing of any sales, subject to the satisfaction of certain conditions, are solely at the option of the Company, and the Company is under no obligation to sell any securities under the Purchase Agreement.
On April 10, 2023, the Company delivered to BRPC II all documents required to be delivered under Section 7.1(iv) of the Purchase Agreement (the “Closing”). Under the applicable Nasdaq Stock Market LLC (“Nasdaq”) rules, the Company cannot issue or sell any shares of common stock pursuant to the Purchase Agreement, and BRPCII shall not purchase or acquire any shares of common stock pursuant to the Purchase Agreement, to the extent that after giving effect thereto, the aggregate number of shares of common stock that would be issued pursuant to the Purchase Agreement and the transactions contemplated thereby would exceed 111,747,196 shares, which number of shares is equal to 19.99% of the total number of shares of the Company’s common stock issued and outstanding immediately prior to the Closing, which number of shares will be reduced, on a share-for-share basis, by the number of shares of common stock issued or issuable pursuant to any transaction or series of transactions that may be aggregated with the transactions contemplated by the Purchase Agreement under the applicable rules of Nasdaq (the “Exchange Cap”), unless the Company obtains stockholder approval to issue shares in excess of the Exchange Cap in accordance with applicable Nasdaq rules; provided, however, the Exchange Cap will not be applicable to the transactions contemplated hereby, solely to the extent that (and only for so long as) the average per share purchase price paid by BRPC II equals or exceeds $0.32.
Equity Proceeds Requirements
As previously disclosed, on March 30, 2023, the Company entered into a waiver and amendment (the “Fourth Amendment”) to the Amended Credit Agreement. The Fourth Amendment waived certain events of default under the Credit Agreement related to negative and affirmative covenants. The Fourth Amendment also revised provisions of the Credit Agreement relating to the Equity Commitment (as defined in the Credit Agreement) to reflect the Company’s entry into an at-the-market sales agreement, dated March 30, 2023, by and between the Company and B. Riley Securities, Inc. (the “ATM Agreement”) and the Purchase Agreement (together with the ATM Agreement, the “Equity Documents”). In particular, the Fourth Amendment set forth: (i) the requirements (the “Equity Requirements”) to receive minimum Specified Equity Proceeds (as defined in the Fourth Amendment) or (ii) to demonstrate the Minimum Cumulative Specified Equity Proceeds (as defined in the Fourth Amendment). These testing periods are weekly for the next 8 out of 11 weeks requiring a minimum raise with a Minimum Cumulative Specified Equity Proceeds of approximately $232 million by June 27, 2023 and then $12.5 million weekly thereafter subject to exceptions.